

Aviso de Derechos para emisoras del

FECHA: 28/06/2024



BOLSA MEXICANA DE VALORES, S.A.B DE C.V, INFORMA:

FOLIO DE REFERENCIA DEL EVENTO CORPORATIVO	227170
FOLIO DE REFERENCIA INDEVAL	734046C005
TIPO DE MENSAJE	Replace
COMPLETO / INCOMPLETO	COMPLETE
CONFIRMADO / NO CONFIRMADO	CONFIRMED

CLAVE DE COTIZACIÓN	NBSE
RAZÓN SOCIAL	NEUBASE THERAPEUTICS, INC.
SERIE	*
ISIN	US64132K2015
MERCADO PRINCIPAL	NASDAQ

TIPO DE EVENTO	LIQUIDATION DIVIDEND/LIQUIDATION PAYMENT
-----------------------	--

DETALLE DEL TIPO DE EVENTO
Occurrence Type
FINAL

MANDATORIO / OPCIONAL / VOLUNTARIO	Mandatory
---	-----------

OPCIÓN	1
TIPO	Cash
DEFAULT	true

TRANSACCIÓN	Cash Movement
--------------------	---------------

Aviso de Derechos para emisoras del



FECHA: 28/06/2024

CREDIT / DEBIT	Credit
-----------------------	--------

TRANSACCIÓN	Securities Movement
CREDIT / DEBIT	Debit

VALORES A RECIBIR	
	US64132K2015

NOTAS DEL EVENTO CORPORATIVO

NOTA

(11/03/2024)

On February 22, 2024, the board of directors (the Board) of NeuBase Therapeutics, Inc. determined that it is in the best interests of the Company s stockholders for the Company to dissolve, liquidate and distribute to stockholders its available assets.

The Board unanimously approved the liquidation and dissolution of the Company and expects to in the near future approve a formal plan of dissolution in respect of the liquidation and dissolution, subject to the approval of the Company s stockholders.

The Company plans to hold a special meeting of stockholders at a time, date and location to be announced to seek approval of the liquidation and dissolution of the Company and the Plan of Dissolution and will file proxy materials relating to the Special Meeting with the Securities and Exchange Commission.

The Board reserves the right to abandon the proposed liquidation and dissolution and the Plan of Dissolution, even if approved by the Company s stockholders, if the Board, in its discretion, determines that the liquidation and dissolution of the Company or the Plan of Dissolution is no longer in the best interests of the Company and its stockholders.